Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced the results from a preclinical program that showed that MBX-102/JNJ-39659100, the company’s lead insulin sensitizer, potently reduces inflammation in mouse and rat models of diabetes. (MBX-102/JNJ-39659100 was previously referred to as metaglidasen).

Metabolex investigators, presenting at the Keystone Symposium in Keystone, Colo., compared the effect of MBX-102/JNJ-39659100, rosiglitazone and a vehicle treatment. Both mice and rats treated with either active compound demonstrated substantially reduced inflammation and macrophage infiltration in adipose tissue. In addition, treatment with MBX102/JNJ39659100 suppressed the expression of key inflammatory genes in adipose tissue and macrophages.

In addition to its role in reducing inflammation, a 217-patient Phase 2 study showed that MBX-102/JNJ-39659100 has a positive effect on glucose and lipid levels and was well-tolerated. MBX-102/JNJ-39659100 has the potential to offer efficacy similar to drugs such as rosiglitazone and pioglitazone from the thiazolidinedione (TZD) class. However, MBX-102/JNJ-39659100 is not a TZD and has a different mechanism of action than the TZDs, and the Phase 2 research suggested that the patients receiving MBX-102/JNJ-39659100 may be spared the edema and weight gain commonly seen in patients treated with TZDs.

Metabolex is now testing MBX-102/JNJ-39659100 in a 400-patient Phase 2/3 clinical trial. In June 2006, Metabolex entered into a strategic alliance with Ortho-McNeil, Inc., giving Ortho-McNeil an exclusive license for worldwide development and commercialization of MBX-102/JNJ-39659100.

About Metabolex
Metabolex is a privately held biotechnology company dedicated to the discovery and development of novel therapeutics to transform the treatment of diabetes and related metabolic disorders. Metabolex has drawn on its deep understanding of diabetes to create the largest database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has three clinical-stage compounds: MBX-102/JNJ- 39659100, in Phase 2/3; MBX-2044, in Phase 2a; and MBX-8025, being studied in dyslipidemia, which has completed Phase 1 studies. Both MBX-102/JNJ-39659100 and MBX-2044 are second-generation insulin sensitizers that lower blood glucose without the safety and tolerability issues associated with currently marketed products. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ-39659100 and MBX-2044. For additional information about Metabolex and its development pipeline, visit www.metabolex.com .

Source: Metabolex, Inc.

Related Health News:

1. Study Shows Nonsurgical Treatment Reduces Neck Pain There's a new study out today that shows that a nonsurgical treatment reduces neck pain without a significant risk of paralysis. This is the largest...
2. The Official Diabetes Blog Says Diabetes Sufferers Still Searching For Critical Information Diabetes website, The Official Diabetes Blogâ„¢, has released data showing the need for increased awareness about the symptoms and treatment of Diabetes. A survey conducted...
3. Diabetes Sufferers Share Their Stories on the Official Diabetes Blog Diabetes sufferers around the world are sharing their stories and experiences to help others who are looking for answers about diabetes. Australian-based website, The Official...
4. Exubera Effective in Diabetes Patients Who Have Respiratory Infections Adult patients with diabetes who took Exubera(R) (insulin human [rDNA origin]) inhalation powder were able to safely maintain good blood sugar control even if they...
5. FDA Extends Marketing Exclusivity for LEVAQUIN According to a press release today, the U.S. Food and Drug Administration (FDA) has granted LEVAQUIN(R) (levofloxacin) an additional six months of marketing exclusivity, known...